Novo Nordisk sued rival Eli Lilly in a US federal court, accusing the US drugmaker of false advertising in claiming its weight-loss medicines outperform Novo's drugs. @MaggieFick explains
Novo Nordisk $NVO secured European Commission 🇪🇺 marketing authorization for Wegovy pill, a once-daily oral semaglutide 25 mg for adult weight management